TY - JOUR T1 - Multi-omics study revealing tissue-dependent putative mechanisms of SARS-CoV-2 drug targets on viral infections and complex diseases JF - medRxiv DO - 10.1101/2020.05.07.20093286 SP - 2020.05.07.20093286 AU - Jie Zheng AU - Yuemiao Zhang AU - Yi Liu AU - Denis Baird AU - Xingzi Liu AU - Lin Wang AU - Hong Zhang AU - George Davey Smith AU - Tom R Gaunt Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/11/2020.05.07.20093286.abstract N2 - Drug target prioritization for new targets and drug repurposing of existing drugs for COVID-19 treatment are urgently needed for the current pandemic. COVID-19 drugs targeting human proteins will potentially result in less drug resistance but could also exhibit unintended effects on other complex diseases. Here we pooled 353 candidate drug targets of COVID-19 from clinical trial registries and the literature and estimated their putative causal effects in 11 SARS-CoV-2 related tissues on 622 complex human diseases. By constructing a disease atlas of drug targets for COVID-19, we prioritise 726 target-disease associations with evidence of causality using robust Mendelian randomization (MR) and colocalization evidence (http://epigraphdb.org/covid-19/ctda/). Triangulating these MR findings with historic drug trial information and the druggable genome, we ranked and prioritised three genes DHODH, ITGB5 and JAK2 targeted by three marketed drugs (Leflunomide, Cilengitide and Baricitinib) which may have repurposing potential with careful risk assessment. This study evidences the value of our integrative approach in prioritizing and repurposing drug targets, which will be particularly applicable when genetic association studies of COVID-19 are available in the near future.One Sentence Summary Integrating multi-omic causal evidence with drug trials to prioritize drug targets for COVID-19 treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJZ is funded by a Vice-Chancellor Fellowship from the University of Bristol. This research was also funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/1, MC_UU_00011/4). This study was funded/supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol (TRG). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. YMZ is supported by National Natural Science Foundation of China (81800636). HZ is supported by the University of Michigan Health System–Peking University Health Science Center Joint Institute for Translational and Clinical Research (BMU2017JI007).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data needed for the analysis were available via MR-Base platform. The results is available via the EpiGraphDB platform http://epigraphdb.org/covid-19/ctda/ http://epigraphdb.org/covid-19/ctda/ ER -